Step by Step

INTRODUCTION

Professional Profile Details

3/10/2026 - Medical Grand Rounds: Ending the HIV Epidemic: Recent Updates and Challenges in HIV Prevention and Cure Research

QUIZ

EVALUATION

CERTIFICATE

INTRODUCTION

Credit Hours: 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Describe the clinical and public health rationale for achieving sustained HIV remission without continuous antiretroviral therapy.
  • Explain the biological and virologic mechanisms that enable HIV to persist despite currently available antiretroviral therapies.
  • Identify key scientific, clinical, and implementation barriers to achieving sustained HIV remission.
  • Evaluate emerging and innovative therapeutic strategies under investigation for achieving HIV remission.
  • Estimate the likelihood of achieving sustained HIV remission for most persons living with HIV based on current evidence.
  • Apply strategies to increase patient linkage to biomedical HIV prevention options, including pre-exposure prophylaxis (PrEP).
  • Select the most appropriate HIV prevention options to improve client success based on individual risk profiles and clinical context.
  • Improve patient outcomes by appropriately referring patients for post-exposure prophylaxis for sexually transmitted infections.

Suggested Additional Reading:

  1. Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N Engl J Med 2025;392:1261-1276.
  2. Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med 2021;385:595-608.
  3. Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet 2022;399:1779-1789.
  4. Chou, Roger, et al. "Preexposure prophylaxis for the prevention of HIV: updated evidence report and systematic review for the US Preventive Services Task Force." JAMA 330.8 (2023): 746-763.
  5. Lewin SR, Bansbach C, Kemps D, Mathae L, Das KT, McCune JM, Deeks SG, Ndung'u T; HIV Cure Gene Therapy Target Product Profile Working Group. Target product profile for cell-based and gene-based therapies to achieve a cure for HIV. Lancet HIV. 2025 Feb;12(2):e154-e162. doi: 10.1016/S2352-3018(24)00277-7. Epub 2025 Jan 3. PMID: 39761679.
  6. Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong MAWP, Lambotte O, Lamplough R, Ndung'u T, Sugarman J, Tiemessen CT, Vandekerckhove L, Lewin SR; International AIDS Society (IAS) Global Scientific Strategy working group. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nat Med. 2021 Dec;27(12):2085-2098. doi: 10.1038/s41591-021-01590-5. Epub 2021 Dec 1. PMID: 34848888.
  7. Halvas EK, Joseph KW, Brandt LD, Guo S, Sobolewski MD, Jacobs JL, Tumiotto C, Bui JK, Cyktor JC, Keele BF, Morse GD, Bale MJ, Shao W, Kearney MF, Coffin JM, Rausch JW, Wu X, Hughes SH, Mellors JW. HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus. J Clin Invest. 2020 Nov 2;130(11):5847-5857. doi: 10.1172/JCI138099. PMID: 33016926; PMCID: PMC7598056.

Authors:
John Mellors, PhD — Distinguished Professor of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine
No relationships with industry relevant to the content of this educational activity have been disclosed.
Sharon Hillier, PhD — Professor of Obstetrics, Gynecology and Reproductive Sciences and Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine
No relationships with industry relevant to the content of this educational activity have been disclosed.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Each physician should only claim credit commensurate with the extent of their participation in the activity.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

The University of Pittsburgh is an affirmative action, equal opportunity institution.